The public recently praised a Chinese doctor in Zhengzhou city because the 4 pills of anti-allergy drug that she prescribed cost only 4 Chinese cents (less than 1 US cent) to treat a 2-year-old patient’s rashes. Many Chinese netizens wish more doctors could behave like this one since expensive drugs are becoming prevalent to treat […]
On December 11, 2013, the Food Drug Administration (FDA) issued guidelines aimed at phasing out the use of antibiotics that are critical to human health in food-producing animals, including penicillin, azithromycin and tetracycline. Aside from treating infections in animals, livestock producers have been using antibiotics to induce growth in an animal and maximize feed. The […]
Posted in FDA ; Tagged: animal, Animal Health Institute, Antibiotic resistance, Antibiotics, Bayer, Center for Veterinary Medicine, drug, drug companies, drug resistance, drugs, Elanco, infectious diseases, Johns Hopkins, Johns Hopkins Center for a Livable Future, Merck, Novartis, Pharmaceuticals, public health, Sanofi, Zoetis.
A committee formed by the Institute of Medicine (IOM), National Academy of Science, and chaired by O’Neill Institute for National and Global Health Law Faculty Director and Georgetown University Law Center Professor Lawrence Gostin has issued a new report, “Countering the Problem of Falsified and Substandard Drugs,” which offers recommendations to the United States and […]
Post by Kevin Outterson Associate Professor & Co-Director of the Health Law Program BU Law Last week, Rep. Peter Welch (D-VT) introduced a bill (H.R. 4752) to overturn the 2003 ban on government-led price negotiations for Medicare Part D drug plans. The bill has 73 co-sponsors so far. While perhaps well intentioned, this bill will […]
Kevin Outterson, Boston University Law The following is a summary of the drug & device provisions in HR 3962, as passed by the House on Saturday, Nov. 7. Winners: PhRMA; BIO; seniors in the donut hole; transparency PhRMA & BIO escape with minimal net financial costs; on balance the bill might be revenue positive for […]
Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute
Or sign up for our RSS Feed
The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.